Log in to search using one of your social media accounts:


Antibody therapy reduces flare-ups in treatment-resistant COPD

Results come from two trials presented at European Respiratory Society International Congress Related items fromOnMedica Making sense of the new LABAs and LAMAs for COPD Physical activity decreases risk of dying in COPD End-of-life care in COPD Diagnosis of COPD needs to be improved CVD event risk raised soon after COPD exacerbations
Source: OnMedica Latest News - Category: UK Health Source Type: news

Related Links:

The FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta, GlaxoSmithKline) for patients with COPD.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
Medication therapy management plays an important role in helping patients learn how to manage COPD and decrease complications. Learn about MTM interventions for COPD in this primer.U.S. Pharmacist
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news
The FDA has approved the triple inhaler developed by GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) to treat chronic obstructive pulmonary disease, the companies reported today. The Trelega Ellipta dry powder inhaler uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD manage the condition. It is the first once-daily product approved in the U.S. that combines three active molecules in a single inhaler for COPD patients. Get the full story at our sister site, Drug Delivery Business News. The post FDA approves GSK’s 3-in-1 Trelega Ellipta inhaler appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news
(Natural News) Chronic obstructive pulmonary disease (COPD) is a life-threatening condition that results in obstructed airflow and difficulty breathing. There are two main illnesses associated with COPD: Chronic bronchitis, which affects more than 10 million Americans, and emphysema, which over 4.7 million Americans have been diagnosed with. While the most common cause of COPD is...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Publication date: Available online 18 September 2017 Source:Social Science & Medicine Author(s): Dominic Malcolm, Mark W. Orme, Mike D. Morgan, Lauren B. Sherar This paper draws on Elias's sociology of knowledge to provide a critical assessment of illness narratives. Focusing on a cohort of chronic obstructive pulmonary disease (COPD) patients (n = 26), the paper employs a comparative analysis of mixed method data derived from qualitative interviews, quantitative questionnaires, and physiological and accelerometer testing. The article firstly compares four narratives conveyed in interviews with the broader p...
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
CONCLUSIONS: In people with COPD, PDE4 inhibitors offered benefit over placebo in improving lung function and reducing the likelihood of exacerbations; however, they had little impact on quality of life or symptoms. Gastrointestinal adverse effects and weight loss were common, and safety data submitted to the US Food and Drug Administration (FDA) have raised concerns over psychiatric adverse events with roflumilast. The findings of this review give cautious support to the use of PDE4 inhibitors in COPD. They may be best used as add-on therapy in a subgroup of people with persistent symptoms or exacerbations despite optimal...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Conclusions Seven out of ten patients who were part of the workforce prior to IE and alive at discharge were part of the workforce one year later. Younger age, higher socioeconomic status, and absence of major comorbidities were associated with return to the workforce.
Source: American Heart Journal - Category: Cardiology Source Type: research
(Reuters) - GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD).
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
London UK – 18 September 2017 -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Abstract Obstructive airways inflammatory diseases sometimes show overlapping symptoms that hinder their early and correct diagnosis. Current clinical tests are tedious and are of inadequate specificity in special population such as the elderly and children. Therefore, we are developing tandem mass spectrometric (MS/MS) methods for targeted analysis of urine biomarkers. Recently, proton-nuclear magnetic resonance ((1)H-NMR) analysis proposed 50 urinary metabolites as potential diagnostic biomarkers among asthma and chronic obstructive pulmonary disease (COPD) patients. Metabolites are divided into 3 groups based o...
Source: Analytica Chimica Acta - Category: Chemistry Authors: Tags: Anal Chim Acta Source Type: research
More News: Chronic Obstructive Pulmonary | Politics | Respiratory Medicine | UK Health